Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study

Evan B. Cunningham*, Behzad Hajarizadeh, Olav Dalgard, Janaki Amin, Margaret Hellard, Graham R. Foster, Philip Bruggmann, Brian Conway, Markus Backmund, Geert Robaeys, Tracy Swan, Philippa S. Marks, Sophie Quiene, Tanya L. Applegate, Martin Weltman, David Shaw, Adrian Dunlop, Julie Bruneau, Håvard Midgard, Stefan BourgeoisMaria Christine Thurnheer, Gregory J. Dore, Jason Grebely, The ACTIVATE Study Group

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
12 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study'. Together they form a unique fingerprint.

Medicine & Life Sciences